Side-by-side · Research reference

AOD-9604vsCagrilintide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/47 cited

BPhase 3HUMAN-REVIEWED35/64 cited

AOD-9604

HGH 176-191 · β3-AR Lipolytic

250–300 mcgDaily doseHeffernan 2001

Phase 2Evidence levelHeffernan 2001 Ng 2000

~30 minHalf-life

SQ · Abdomen · Daily fasted

Cagrilintide

Long-Acting Amylin Analogue · Phase 3

7.5%Additional weight loss vs semaglutideAhmed 2026

Once weeklyDosing frequencyBailey 2026

Dual AMYR/CTRReceptor agonismBailey 2026

SQ · Once WeeklyBailey 2026

01Mechanism of Action

Parameter

AOD-9604

Cagrilintide

Primary target

β3-adrenergic receptor (proposed)Ng 2000

Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026

Pathway

β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2000

AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026

Downstream effect

Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001

Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026 Yamauchi 2026

Feedback intact?

No GH-axis or IGF-1 feedback

Yes — acts via physiological amylin pathways

Origin

Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2000

Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026

Antibody development

—

02Dosage Protocols

Parameter

AOD-9604

Cagrilintide

Standard dose

250–300 mcg / dayHeffernan 2001

Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.

—

Frequency

Once daily, fasted

Once weekly (subcutaneous)Bailey 2026

Long-acting formulation.

Lower / starter dose

150 mcg / day

—

Evidence basis

Phase 2 trials + animal-strongHeffernan 2001 Ng 2000

Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026 Ahmed 2026

Duration

8–12 weeks per cycle

26–52 weeks in trialsYamauchi 2026

Reconstitution

Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL

—

Timing

Morning fasted preferred (pre-cardio)

Aligns with circadian lipolysis.

—

Half-life

~30 min plasma

—

Standard dose (combination)

—

Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026

Phase 3 REDEFINE 5 trial dosing.

Monotherapy dosing

—

Dose-dependent, under investigation

Monotherapy trials reported in meta-analysis.

Route

—

Subcutaneous injectionBailey 2026

03Metabolic / Fat Loss Evidence

Parameter

AOD-9604

Cagrilintide

Weight loss vs semaglutide

—

7.47% greater percentage weight lossAhmed 2026

CagriSema combination vs semaglutide monotherapy (meta-analysis).

Absolute weight change

—

Significantly greater absolute weight reductionAhmed 2026

Mean difference favoring combination therapy.

Mechanism

—

Central satiety inductionBailey 2026

BMI reduction

—

Significant BMI reduction vs comparatorAhmed 2026

Glycemic benefit

—

Reduced fasting glucose and HbA1cAhmed 2026

Synergistic effect with semaglutide in combination.

Lipid effects

—

Improvements in total cholesterol, LDL-C, HDL-C, VLDL-C, triglyceridesAhmed 2026

Body composition

—

Predominant fat loss with weight reduction

Mitochondrial function

—

In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026

C2C12 myotube study; clinical relevance under investigation.

Combination rationale

—

Multi-pathway approach: amylin (satiety) + GLP-1 (incretin)Lempesis 2026

Key publications

—

REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026 Ahmed 2026 Bailey 2026

04Side Effects & Safety

Parameter

AOD-9604

Cagrilintide

Injection site reaction

Mild erythema

—

GI symptoms

Rare mild nausea

—

Cardiovascular

Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)

—

IGF-1 elevation

None — designed to lack GH-axis activityHeffernan 2001

—

Insulin sensitivity

Neutral — no glucose impairmentHeffernan 2001

—

Cancer risk

No GH/IGF-1 axis activity → lower theoretical risk vs HGH

—

Pregnancy / OB

Avoid

—

Gastrointestinal

—

Nausea, diarrhea (common with incretin-based therapies)Pardali 2026

Dietary management and nutritional monitoring recommended.

Injection site reactions

—

Local reactions possible with subcutaneous administration

Safety profile

—

Generally consistent with incretin-based therapies

Phase 3 and meta-analysis safety data.

Tolerability

—

Tolerability considerations similar to GLP-1RAs

Muscle preservation

—

Lean mass considerations during weight loss

In vitro mitochondrial effects observed; clinical impact under investigation.

Absolute Contraindications

AOD-9604

·Pregnancy / breastfeeding
·Severe cardiovascular disease (caution with β-receptor agonists)

Cagrilintide

·Hypersensitivity to cagrilintide or formulation components

Relative Contraindications

AOD-9604

·Concurrent β-blocker therapy (theoretical antagonism)
·Pheochromocytoma

Cagrilintide

·Severe gastrointestinal disease
·History of pancreatitis (incretin-based therapy consideration)

05Administration Protocol

Parameter

AOD-9604

Cagrilintide

1. Reconstitution

Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.

Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026

2. Injection site

SQ — abdomen preferred. Rotate sites.

Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026 Bailey 2026

3. Timing

Morning, fasted, ideally pre-cardio for amplified fat oxidation.

Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.

5. Needle

29–31G, 4–8 mm insulin syringe.

Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026

06Stack Synergy

AOD-9604

+ MOTS-c

Moderate

View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604: 250–300 mcg SQ · morning fasted (daily)
MOTS-c: 5 mg SQ · 2–3× per week (pre-workout)
Primary benefit: Fat mobilisation + mitochondrial oxidation, no IGF-1 concern

Cagrilintide

+ Semaglutide

Strong

View Semaglutide →

Cagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.

CagriSema: Cagrilintide 2.4 mg + Semaglutide 2.4 mg
Frequency: Once weekly subcutaneous
Duration: 26–52 weeks (trial data)
Primary benefit: Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation

Yamauchi 2026 Ahmed 2026 Bailey 2026